Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Dec 05, 2023
Episode
191
Soundcloud
Share
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.
Guest
Coral Olazagasti
MD
Assistant Professor
Sylvester Cancer Center, University of Miami
Jonathan Spicer
MD, PhD, FRCS
Division of Thoracic Surgery Director
McGill University
